AFFF cancer lawsuit

New Research Connections AFFF Foam Exposure Raising Thyroid Cancer Risk

As evidence of hazardous firefighting foam possibly contributing to increased thyroid cancer rates in exposed persons mounts, a current study raises further concerns

Monday, April 7, 2025 - New studies are clarifying a major health risk connected to long-term AFFF firefighting foam use. Widely employed in military bases, airports, and industrial sites, this kind of foam has previously drawn criticism for its chemical components, especially those that linger in the human body and the surroundings. Scientists are now discovering more robust links between AFFF exposure and higher thyroid cancer risk. Many people can relate too much to this realization. It follows the trend seen in AFFF cancer litigation, in which a widely used substance turned out to have hidden risks. An AFFF cancer attorney would note that typically decades of preventable damage result from delayed warnings and inadequate testing. Particularly among first responders, airport employees, and neighbors living near places where the foam was routinely deployed, the same irritation is beginning to develop around the AFFF issue. Thyroid cancer is especially concerning since it can be challenging to find early on and is usually associated with abnormalities in hormone control. AFFF's chemicals, particularly PFAS compounds, are well recognized to mess with the endocrine system, which regulates hormones all throughout the body. According to the current studies, regular, even low-level exposure to these drugs could cause aberrant thyroid function and over time raise cancer risk. Although earlier research had also connected PFAS to various cancers and immunological issues, the mounting data on thyroid cancer is driving many health professionals to demand a quick response. Those most impacted, like ground crews and firefighters, are now encouraged to pay closer attention to their thyroid health and have tests as suggested as needed.

The practical ramifications are really significant. Many employees have handled this foam without health warnings or protective gear over the years. In other cases, individuals were even exposed during training drills involving significant AFFF use. Residents close to military sites or airfields might have been unintentionally exposed to environmental contamination or drinking water. Now, with this fresh research in hand, people are starting to wonder why more wasn't done to safeguard them and how much was known. Like the indignation following disclosures in firefighter cancer claims, the sense of betrayal is mounting. People felt their surroundings and employment were safe; now they are learning this was not always true. Reform calls are getting louder. Widespread thyroid tests for those in high-risk categories are under demand by health activists. Legal experts say if affected people start to come forward, this new link might lead to a tsunami of litigation. Public organizations and businesses are under increasing pressure at the same time to phase out AFFF entirely and clean polluted sites. While several departments have already shifted to safer, fluorine-free substitutes, many others still run AFFF as their regular operations. With this research tying the foam to such a specific and potent type of cancer, more companies should handle the problem with the urgency it merits.

Information provided by AFFFLawsuitCenter.com, a website devoted to providing news about AFFF and PFAS cancer, lymphoma and leukaemia claims, including a free no-cost, no-obligation AFFF Lawsuit Claim.

More Recent AFFF Lawsuit News:

View all AFFF Lawsuit News

No-Cost, No-Obligation Claim Review for Persons or Families of Persons Who Developed Cancer, Lymphoma or Leukaemia After Exposure to Firefighting Foam

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.


Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.